Lantheus Holdings Inc (LNTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lantheus Holdings Inc (LNTH) has a cash flow conversion efficiency ratio of 0.083x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($90.18 Million) by net assets ($1.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lantheus Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Lantheus Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LNTH total debt and obligations for a breakdown of total debt and financial obligations.
Lantheus Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lantheus Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
-0.069x |
|
Delek Group
TA:DLEKG
|
-0.127x |
|
Sonoco Products Company
NYSE:SON
|
0.088x |
|
Teleflex Incorporated
NYSE:TFX
|
0.049x |
|
Outfront Media Inc
NYSE:OUT
|
0.161x |
|
Hess Midstream Partners LP
NYSE:HESM
|
0.607x |
|
Cochin Shipyard Limited
NSE:COCHINSHIP
|
-0.052x |
|
Sectra AB (publ)
ST:SECT-B
|
0.023x |
Annual Cash Flow Conversion Efficiency for Lantheus Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Lantheus Holdings Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see LNTH stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.09 Billion | $390.14 Million | 0.358x | -28.50% |
| 2024-12-31 | $1.09 Billion | $544.75 Million | 0.501x | +33.82% |
| 2023-12-31 | $815.89 Million | $305.26 Million | 0.374x | -40.63% |
| 2022-12-31 | $447.15 Million | $281.78 Million | 0.630x | +442.84% |
| 2021-12-31 | $464.44 Million | $53.92 Million | 0.116x | +264.07% |
| 2020-12-31 | $514.21 Million | $16.40 Million | 0.032x | -95.45% |
| 2019-12-31 | $114.60 Million | $80.38 Million | 0.701x | -18.61% |
| 2018-12-31 | $71.00 Million | $61.19 Million | 0.862x | -63.35% |
| 2017-12-31 | $23.29 Million | $54.78 Million | 2.352x | +604.63% |
| 2016-12-31 | $-106.52 Million | $49.64 Million | -0.466x | -296.81% |
| 2015-12-31 | $-185.29 Million | $21.76 Million | -0.117x | -142.47% |
| 2014-12-31 | $-239.27 Million | $11.59 Million | -0.048x | -173.26% |
| 2013-12-31 | $-235.52 Million | $-15.57 Million | 0.066x | +2976.73% |
| 2012-12-31 | $-173.10 Million | $-372.00K | 0.002x | -- |
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more